Healthcare
Editas Medicine, Inc.(EDIT)
Live Price
Offline$2.69
+5.49% today
1Y Change
+22.81%
Window
Jun 27, 2025 โ Jun 24, 2026
- Market Cap
- $300.00M
- Revenue Growth
- +25.4%
- EPS Growth
- +37.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 27, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Editas Medicine, Inc. (EDIT) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $2.69 and up 22.8% across the available one-year price window (Jun 27, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +25.4%, EPS growth of +37.5%, a dividend yield of 0.0%. What stands out right now is revenue +25.4%, EPS +37.5%, free cash flow +24.3% with operating margin -251.3% and ROIC -77.5%. Valuation already assumes a fairly strong business story at price/sales 8.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines EDIT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+25.4% vs +7.6% peer median
Operating Margin
Below sector median
-251.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +25.4% and EPS at +37.5%, with operating margin around -251.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -4.2% | -17.3% | -13.4% |
2026 Mar 9, 2026 | +77.8% | +13.8% | +9.5% | +18.1% |
2025 Nov 10, 2025 | +26.3% | +5.6% | +2.4% | -3.2% |
Benchmark Edge
EDIT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EDIT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EDIT Max Drawdown
-59.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EDIT and SPY.
Company Overview
Editas Medicine, Inc.
NASDAQ Global Select
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
- Leadership
- Gilmore O'Neill
- IPO Date
- Feb 3, 2016
- Employees
- 246
- Street Address
- 11 Hurley Street
- Mailing
- Cambridge, MA, 02141
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 401 9000
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.3
- Price/Book
- 67.5
Growth
- Revenue
- +25.4%
- EPS
- +37.5%
- Free Cash Flow
- +24.3%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -251.3%
- Net Margin
- -303.8%
- ROE
- -677.4%
- ROIC
- -77.5%
Balance Sheet
- Debt/Equity
- 3.92
- Current Ratio
- 3.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.